CR20220561A - Nuevos inhibidores macrocíclicos de la quinasa de lrrk2 - Google Patents
Nuevos inhibidores macrocíclicos de la quinasa de lrrk2Info
- Publication number
- CR20220561A CR20220561A CR20220561A CR20220561A CR20220561A CR 20220561 A CR20220561 A CR 20220561A CR 20220561 A CR20220561 A CR 20220561A CR 20220561 A CR20220561 A CR 20220561A CR 20220561 A CR20220561 A CR 20220561A
- Authority
- CR
- Costa Rica
- Prior art keywords
- kinase inhibitors
- lrrk2 kinase
- new macrocyclic
- macrocyclic lrrk2
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Compuestos de fórmula (I): donde R, X1, X2, X3, Z1, Z2, Z3, A y Ra son como se definen en la descripción. Medicamentos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20315236 | 2020-05-06 | ||
| EP21305112 | 2021-01-28 | ||
| PCT/EP2021/061827 WO2021224320A1 (en) | 2020-05-06 | 2021-05-05 | New macrocyclic lrrk2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220561A true CR20220561A (es) | 2023-02-17 |
Family
ID=75746649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220561A CR20220561A (es) | 2020-05-06 | 2021-05-05 | Nuevos inhibidores macrocíclicos de la quinasa de lrrk2 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230357269A1 (es) |
| EP (1) | EP4146658A1 (es) |
| JP (1) | JP2023523863A (es) |
| KR (1) | KR20230006560A (es) |
| CN (1) | CN115996932A (es) |
| AU (1) | AU2021267691A1 (es) |
| BR (1) | BR112022022511A2 (es) |
| CA (1) | CA3182162A1 (es) |
| CL (1) | CL2022003070A1 (es) |
| CO (1) | CO2022015871A2 (es) |
| CR (1) | CR20220561A (es) |
| DO (1) | DOP2022000242A (es) |
| IL (1) | IL297867A (es) |
| MX (1) | MX2022013861A (es) |
| PE (1) | PE20230612A1 (es) |
| TW (1) | TW202208379A (es) |
| UY (1) | UY39199A (es) |
| WO (1) | WO2021224320A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202304935A (zh) * | 2021-03-18 | 2023-02-01 | 法商施維雅藥廠 | 新穎的巨環lrrk2激酶抑制劑 |
| CN117425660A (zh) * | 2022-05-18 | 2024-01-19 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
| WO2023240140A1 (en) * | 2022-06-08 | 2023-12-14 | Blossomhill Therapeutics, Inc. | Indazole macrocycles and their use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2583477T3 (es) * | 2011-09-30 | 2016-09-21 | Ipsen Pharma S.A.S. | Inhibidores macrocíclicos de cinasa de LRRK2 |
| US9718818B2 (en) * | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| EA032838B1 (ru) | 2014-09-17 | 2019-07-31 | Онкодизайн С.А. | Макроциклические ингибиторы lrrk2-киназы |
| WO2018006931A1 (en) | 2016-07-04 | 2018-01-11 | Telefonaktiebolaget Lm Ericsson (Publ) | Pipelined analog-to-digital converter |
| CA3049820A1 (en) | 2017-01-25 | 2018-08-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds for inhibiting lrrk2 kinase activity |
| WO2018155916A2 (ko) | 2017-02-22 | 2018-08-30 | 재단법인 대구경북첨단의료산업진흥재단 | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CA3056030A1 (en) | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
| WO2018217946A1 (en) | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| AR112392A1 (es) | 2017-07-14 | 2019-10-23 | Glaxosmithkline Ip Dev Ltd | Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende |
| EP3694330B1 (en) | 2017-10-11 | 2023-04-19 | Merck Sharp & Dohme LLC | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| WO2019112269A1 (ko) | 2017-12-05 | 2019-06-13 | 주식회사 오스코텍 | Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체 |
| WO2019222173A1 (en) | 2018-05-15 | 2019-11-21 | E-Scape Bio, Inc. | Fused tetrazoles as lrrk2 inhibitors |
| US10759799B2 (en) * | 2018-06-15 | 2020-09-01 | Samumed, Llc | Indazole containing macrocycles and therapeutic uses thereof |
| WO2020006267A1 (en) | 2018-06-27 | 2020-01-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing lrrk2 expression |
-
2021
- 2021-05-05 KR KR1020227042327A patent/KR20230006560A/ko active Search and Examination
- 2021-05-05 TW TW110116241A patent/TW202208379A/zh unknown
- 2021-05-05 PE PE2022002552A patent/PE20230612A1/es unknown
- 2021-05-05 CA CA3182162A patent/CA3182162A1/en active Pending
- 2021-05-05 BR BR112022022511A patent/BR112022022511A2/pt unknown
- 2021-05-05 AU AU2021267691A patent/AU2021267691A1/en active Pending
- 2021-05-05 US US17/923,002 patent/US20230357269A1/en active Pending
- 2021-05-05 EP EP21722503.6A patent/EP4146658A1/en active Pending
- 2021-05-05 JP JP2022567124A patent/JP2023523863A/ja active Pending
- 2021-05-05 WO PCT/EP2021/061827 patent/WO2021224320A1/en active Application Filing
- 2021-05-05 CN CN202180044443.9A patent/CN115996932A/zh active Pending
- 2021-05-05 CR CR20220561A patent/CR20220561A/es unknown
- 2021-05-05 MX MX2022013861A patent/MX2022013861A/es unknown
- 2021-05-05 IL IL297867A patent/IL297867A/en unknown
- 2021-05-06 UY UY0001039199A patent/UY39199A/es unknown
-
2022
- 2022-11-02 DO DO2022000242A patent/DOP2022000242A/es unknown
- 2022-11-03 CO CONC2022/0015871A patent/CO2022015871A2/es unknown
- 2022-11-04 CL CL2022003070A patent/CL2022003070A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022015871A2 (es) | 2022-12-30 |
| DOP2022000242A (es) | 2023-07-31 |
| UY39199A (es) | 2021-11-30 |
| BR112022022511A2 (pt) | 2022-12-13 |
| CL2022003070A1 (es) | 2023-07-07 |
| JP2023523863A (ja) | 2023-06-07 |
| IL297867A (en) | 2023-01-01 |
| EP4146658A1 (en) | 2023-03-15 |
| CA3182162A1 (en) | 2021-11-11 |
| WO2021224320A1 (en) | 2021-11-11 |
| CN115996932A (zh) | 2023-04-21 |
| PE20230612A1 (es) | 2023-04-13 |
| TW202208379A (zh) | 2022-03-01 |
| KR20230006560A (ko) | 2023-01-10 |
| US20230357269A1 (en) | 2023-11-09 |
| AU2021267691A1 (en) | 2022-12-08 |
| MX2022013861A (es) | 2023-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013861A (es) | Nuevos inhibidores macrociclicos de la quinasa de lrrk2. | |
| MX2009008506A (es) | Derivados del pirazol como inhibidores de 11-b-hsd1. | |
| TN2019000263A1 (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| WO2017109488A8 (en) | Cyanopyrrolidine derivatives as inhibitors for dubs | |
| MX2009010595A (es) | Derivados de pirrolopirimidina. | |
| PH12018502513A1 (en) | Sulfonamide compound or salt thereof | |
| GEP20207111B (en) | Heteroaryl compounds for kinase inhibition | |
| MX2014004307A (es) | Inhibidores de proteinas quinasas. | |
| MX2021008356A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
| GEP20207169B (en) | 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | |
| MX2009007302A (es) | Derivados de purina. | |
| MY148107A (en) | Kinase inhibitor | |
| TNSN08191A1 (en) | Kinase inhibitors | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| GEP20156242B (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
| MX2009005071A (es) | Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| WO2020259724A3 (zh) | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 | |
| PH12020550253A1 (en) | Bicyclic compounds for use as rip1 kinase inhibitors | |
| PH12021551251A1 (en) | Heterocyclic compound | |
| NZ592392A (en) | PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
| UY39680A (es) | Nuevos inhibidores macrocíclicos de la quinasa de lrrk2 | |
| MX2021013981A (es) | Inhibidores de la cinasa aurora y usos de los mismos. | |
| WO2023141432A3 (en) | Apol1 inhibitors and methods of use | |
| MX2022001044A (es) | Inhibidor de sglt2/dpp4 y su aplicacion. |